{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,3]],"date-time":"2026-11-03T17:46:07Z","timestamp":1793727967118,"version":"4.6.1"},"reference-count":64,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,10,31]],"date-time":"2025-10-31T00:00:00Z","timestamp":1761868800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2025,10,31]],"date-time":"2025-10-31T00:00:00Z","timestamp":1761868800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["72374119"],"award-info":[{"award-number":["72374119"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100005090","name":"Beijing Nova Program","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100005090","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Commun Med"],"DOI":"10.1038\/s43856-025-01137-6","type":"journal-article","created":{"date-parts":[[2025,10,31]],"date-time":"2025-10-31T16:35:14Z","timestamp":1761928514000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":6,"title":["Digital health technology use in clinical trials of rare diseases: a systematic review"],"prefix":"10.1038","volume":"5","author":[{"ORCID":"https:\/\/orcid.org\/0009-0000-0233-5523","authenticated-orcid":false,"given":"Xiangyun","family":"Mao","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5592-9584","authenticated-orcid":false,"given":"Dian","family":"Zeng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaocong","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David A.","family":"Pearce","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4920-9553","authenticated-orcid":false,"given":"Gareth","family":"Baynam","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Niels H.","family":"Chavannes","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3438-5685","authenticated-orcid":false,"given":"Wendy K.","family":"Chung","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0213-5668","authenticated-orcid":false,"given":"Honghan","family":"Wu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6752-797X","authenticated-orcid":false,"given":"Yih-Chung","family":"Tham","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1532-0029","authenticated-orcid":false,"given":"Shuyang","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3626-7220","authenticated-orcid":false,"given":"Guanqiao","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8448-1264","authenticated-orcid":false,"given":"Tien Yin","family":"Wong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,10,31]]},"reference":[{"key":"1137_CR1","unstructured":"Global Genes. Rare diseases. RARE facts. https:\/\/globalgenes.org\/rare-disease-facts\/ (2024)."},{"key":"1137_CR2","unstructured":"WHO, Global cancer burden growing, amidst mounting need for services. https:\/\/www.who.int\/news\/item\/01-02-2024-global-cancer-burden-growing--amidst-mounting-need-for-services (2024)."},{"key":"1137_CR3","doi-asserted-by":"publisher","first-page":"165","DOI":"10.1038\/s41431-019-0508-0","volume":"28","author":"S Nguengang Wakap","year":"2020","unstructured":"Nguengang Wakap, S. et al. Estimating cumulative point prevalence of rare diseases: analysis of the Orphanet database. Eur. J. Hum. Genet. 28, 165\u2013173 (2020).","journal-title":"Eur. J. Hum. Genet"},{"key":"1137_CR4","doi-asserted-by":"publisher","first-page":"3049","DOI":"10.1016\/j.apsb.2022.02.002","volume":"12","author":"D Sun","year":"2022","unstructured":"Sun, D., Gao, W., Hu, H. & Zhou, S. Why 90% of clinical drug development fails and how to improve it?. Acta Pharm. Sin. B 12, 3049\u20133062 (2022).","journal-title":"Acta Pharm. Sin. B"},{"key":"1137_CR5","doi-asserted-by":"publisher","first-page":"e1002966","DOI":"10.1371\/journal.pmed.1002966","volume":"16","author":"CA Rees","year":"2019","unstructured":"Rees, C. A., Pica, N., Monuteaux, M. C. & Bourgeois, F. T. Noncompletion and nonpublication of trials studying rare diseases: a cross-sectional analysis. PLoS Med. 16, e1002966 (2019).","journal-title":"PLoS Med."},{"key":"1137_CR6","doi-asserted-by":"publisher","first-page":"495","DOI":"10.1038\/d41573-019-00074-z","volume":"18","author":"H Dowden","year":"2019","unstructured":"Dowden, H. & Munro, J. Trends in clinical success rates and therapeutic focus. Nat. Rev. Drug Discov. 18, 495\u2013496 (2019).","journal-title":"Nat. Rev. Drug Discov."},{"key":"1137_CR7","doi-asserted-by":"publisher","first-page":"37","DOI":"10.1038\/s41746-022-00581-1","volume":"5","author":"RKJ Tan","year":"2022","unstructured":"Tan, R. K. J. et al. Digital approaches to enhancing community engagement in clinical trials. npj Digit. Med. 5, 37 (2022).","journal-title":"npj Digit. Med."},{"key":"1137_CR8","doi-asserted-by":"publisher","first-page":"88","DOI":"10.1038\/s41746-023-00841-8","volume":"6","author":"M Mittermaier","year":"2023","unstructured":"Mittermaier, M., Venkatesh, K. P. & Kvedar, J. C. Digital health technology in clinical trials. npj Digit. Med. 6, 88 s41746-023-00841\u20138 (2023).","journal-title":"npj Digit. Med."},{"key":"1137_CR9","doi-asserted-by":"publisher","first-page":"620","DOI":"10.1038\/s41591-022-01775-6","volume":"28","author":"BT Li","year":"2022","unstructured":"Li, B. T. et al. Reimagining patient-centric cancer clinical trials: a multi-stakeholder international coalition. Nat. Med. 28, 620\u2013626 (2022).","journal-title":"Nat. Med."},{"key":"1137_CR10","doi-asserted-by":"publisher","first-page":"2693","DOI":"10.1038\/s41591-023-02489-z","volume":"29","author":"CO Dur\u00e1n","year":"2023","unstructured":"Dur\u00e1n, C. O. et al. Implementation of digital health technology in clinical trials: the 6R framework. Nat. Med. 29, 2693\u20132697 (2023).","journal-title":"Nat. Med."},{"key":"1137_CR11","doi-asserted-by":"publisher","first-page":"101","DOI":"10.1038\/s41746-020-0302-y","volume":"3","author":"OT Inan","year":"2020","unstructured":"Inan, O. T. et al. Digitizing clinical trials. npj Digit. Med. 3, 101 (2020).","journal-title":"npj Digit. Med."},{"key":"1137_CR12","doi-asserted-by":"publisher","first-page":"148","DOI":"10.1016\/j.ccell.2020.06.018","volume":"38","author":"G Li","year":"2020","unstructured":"Li, G. et al. Digitalized adaptation of oncology trials during and after COVID-19. Cancer Cell 38, 148\u2013149 (2020).","journal-title":"Cancer Cell"},{"key":"1137_CR13","doi-asserted-by":"publisher","DOI":"10.1186\/s13023-022-02388-5","volume":"17","author":"J Moore","year":"2022","unstructured":"Moore, J., Goodson, N., Wicks, P. & Reites, J. What role can decentralized trial designs play to improve rare disease studies?. Orphanet J. Rare Dis. 17, 240 (2022).","journal-title":"Orphanet J. Rare Dis."},{"key":"1137_CR14","doi-asserted-by":"publisher","first-page":"168","DOI":"10.1038\/d41573-023-00177-8","volume":"23","author":"R Chen","year":"2024","unstructured":"Chen, R. et al. Trends in rare disease drug development. Nat. Rev. Drug Discov. 23, 168\u2013169 (2024).","journal-title":"Nat. Rev. Drug Discov."},{"key":"1137_CR15","doi-asserted-by":"publisher","first-page":"40","DOI":"10.1038\/s41746-021-00412-9","volume":"4","author":"DV Gunasekeran","year":"2021","unstructured":"Gunasekeran, D. V., Tseng, R. M. W. W., Tham, Y.-C. & Wong, T. Y. Applications of digital health for public health responses to COVID-19: a systematic scoping review of artificial intelligence, telehealth and related technologies. npj Digit. Med. 4, 40 (2021).","journal-title":"npj Digit. Med."},{"key":"1137_CR16","doi-asserted-by":"publisher","first-page":"378","DOI":"10.1038\/d41573-020-00094-0","volume":"19","author":"JC Goldsack","year":"2020","unstructured":"Goldsack, J. C. et al. Remote digital monitoring in clinical trials in the time of COVID-19. Nat. Rev. Drug Discov. 19, 378\u2013379 (2020).","journal-title":"Nat. Rev. Drug Discov."},{"key":"1137_CR17","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0257880","volume":"16","author":"L Cadel","year":"2021","unstructured":"Cadel, L. et al. A scoping review of patient engagement activities during COVID-19: more consultation, less partnership. PLoS ONE 16, e0257880 (2021).","journal-title":"PLoS ONE"},{"key":"1137_CR18","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1136\/jnnp-2016-315106.142","volume":"87","author":"V Ricotti","year":"2016","unstructured":"Ricotti, V. et al. The NorthStar Ambulatory Assessment in Duchenne muscular dystrophy: considerations for the design of clinical trials. J. Neurol. Neurosurg. Psychiatry 87, 149\u2013155 (2016).","journal-title":"J. Neurol. Neurosurg. Psychiatry"},{"key":"1137_CR19","doi-asserted-by":"publisher","first-page":"276","DOI":"10.3390\/jpm12020276","volume":"12","author":"P Kiper","year":"2022","unstructured":"Kiper, P. et al. Combined motor and cognitive rehabilitation: the impact on motor performance in patients with mild cognitive impairment. systematic review and meta-analysis. J. Pers. Med. 12, 276 (2022).","journal-title":"J. Pers. Med."},{"key":"1137_CR20","doi-asserted-by":"publisher","first-page":"1748","DOI":"10.1016\/S0140-6736(15)60025-3","volume":"385","author":"GM Buyse","year":"2015","unstructured":"Buyse, G. M. et al. Efficacy of idebenone on respiratory function in patients with Duchenne muscular dystrophy not using glucocorticoids (DELOS): a double-blind randomised placebo-controlled phase 3 trial.  Lancet 385, 1748\u20131757 (2015).","journal-title":"Lancet"},{"key":"1137_CR21","doi-asserted-by":"publisher","first-page":"393","DOI":"10.1164\/rccm.202002-0328OC","volume":"202","author":"CC Moor","year":"2020","unstructured":"Moor, C. C. et al. Home monitoring in patients with idiopathic pulmonary fibrosis. A randomized controlled trial. Am. J. Respir. Crit. Care Med. 202, 393\u2013401 (2020).","journal-title":"Am. J. Respir. Crit. Care Med."},{"key":"1137_CR22","doi-asserted-by":"publisher","first-page":"87","DOI":"10.1159\/000481264","volume":"95","author":"T Del Corral","year":"2018","unstructured":"Del Corral, T. et al. Effectiveness of a home-based active video game programme in young cystic fibrosis patients. Respiration 95, 87\u201397 (2018).","journal-title":"Respiration"},{"key":"1137_CR23","doi-asserted-by":"publisher","first-page":"1698","DOI":"10.3324\/haematol.2018.190777","volume":"103","author":"HM Schoemans","year":"2018","unstructured":"Schoemans, H. M. et al. The eGVHD App has the potential to improve the accuracy of graft-versus-host disease assessment: a multicenter randomized controlled trial. Haematologica 103, 1698\u20131707 (2018).","journal-title":"Haematologica"},{"key":"1137_CR24","doi-asserted-by":"publisher","first-page":"495","DOI":"10.1038\/d41573-020-00060-w","volume":"19","author":"A Hechtelt Jonker","year":"2020","unstructured":"Hechtelt Jonker, A. et al. Boosting delivery of rare disease therapies: the IRDiRC Orphan Drug Development Guidebook. Nat. Rev. Drug Discov. 19, 495\u2013496 (2020).","journal-title":"Nat. Rev. Drug Discov."},{"key":"1137_CR25","doi-asserted-by":"publisher","DOI":"10.1186\/s13023-023-02684-8","volume":"18","author":"Z Zhao","year":"2023","unstructured":"Zhao, Z., Pei, Z., Hu, A., Zhang, Y. & Chen, J. Analysis of incentive policies and initiatives on orphan drug development in China: challenges, reforms and implications. Orphanet J. Rare Dis. 18, 220 (2023).","journal-title":"Orphanet J. Rare Dis."},{"key":"1137_CR26","unstructured":"Sanders, T. I. The orphan drug act. Progr. Clin. Biol. Res. 127, 207\u2013215 (1983)."},{"key":"1137_CR27","unstructured":"Accelerating Rare disease Cures (ARC) Program. https:\/\/www.fda.gov\/about-fda\/center-drug-evaluation-and-research-cder\/accelerating-rare-disease-cures-arc-program (2022)."},{"key":"1137_CR28","unstructured":"Patient-Centered Action for Rare diseases Encouragement. https:\/\/www.cde.org.cn\/main\/news\/viewInfoCommon\/55f3e6ce1198d6be0f65cfc477d46c05 (2024)."},{"key":"1137_CR29","doi-asserted-by":"publisher","DOI":"10.1186\/s13023-023-02790-7","volume":"18","author":"LJ Fermaglich","year":"2023","unstructured":"Fermaglich, L. J. & Miller, K. L. A comprehensive study of the rare diseases and conditions targeted by orphan drug designations and approvals over the forty years of the Orphan Drug Act. Orphanet J. Rare Dis. 18, 163 (2023).","journal-title":"Orphanet J. Rare Dis."},{"key":"1137_CR30","doi-asserted-by":"publisher","first-page":"261","DOI":"10.1007\/s40290-024-00529-8","volume":"38","author":"G Baynam","year":"2024","unstructured":"Baynam, G. et al. Increasing diversity, equity, inclusion, and accessibility in rare disease clinical trials. Pharm. Med. 38, 261\u2013276 (2024).","journal-title":"Pharm. Med."},{"key":"1137_CR31","doi-asserted-by":"publisher","first-page":"e201965","DOI":"10.1001\/jamanetworkopen.2020.1965","volume":"3","author":"AA Mitani","year":"2020","unstructured":"Mitani, A. A. & Haneuse, S. Small data challenges of studying rare diseases. JAMA Netw. Open 3, e201965 (2020).","journal-title":"JAMA Netw. Open"},{"key":"1137_CR32","doi-asserted-by":"publisher","first-page":"913567","DOI":"10.3389\/fphar.2022.913567","volume":"13","author":"TB Polak","year":"2022","unstructured":"Polak, T. B., Cucchi, D. G. J., Van Rosmalen, J., Uyl-de Groot, C. A. & Darrow, J. J. Generating evidence from expanded access use of rare disease medicines: challenges and recommendations. Front. Pharmacol. 13, 913567 (2022).","journal-title":"Front. Pharmacol."},{"key":"1137_CR33","doi-asserted-by":"publisher","first-page":"1309","DOI":"10.1016\/j.chest.2017.12.018","volume":"153","author":"JK Stoller","year":"2018","unstructured":"Stoller, J. K. The challenge of rare diseases. Chest 153, 1309\u20131314 (2018).","journal-title":"Chest"},{"key":"1137_CR34","doi-asserted-by":"publisher","DOI":"10.1186\/s13063-018-2645-0","volume":"19","author":"RA Crow","year":"2018","unstructured":"Crow, R. A. et al. A checklist for clinical trials in rare disease: obstacles and anticipatory actions\u2014lessons learned from the FOR-DMD trial. Trials 19, 291 (2018).","journal-title":"Trials"},{"key":"1137_CR35","unstructured":"PhD, V. K. FDA perspectives on digital health technologies in clinical trials. Xtalks https:\/\/xtalks.com\/fda-perspectives-on-digital-health-technologies-in-clinical-trials-4185\/ (2025)."},{"key":"1137_CR36","doi-asserted-by":"publisher","first-page":"1042","DOI":"10.1016\/j.chest.2021.04.012","volume":"160","author":"AR Hemnes","year":"2021","unstructured":"Hemnes, A. R. et al. A mobile health intervention to increase physical activity in pulmonary arterial hypertension. Chest 160, 1042\u20131052 (2021).","journal-title":"Chest"},{"key":"1137_CR37","doi-asserted-by":"publisher","first-page":"e55718","DOI":"10.2196\/55718","volume":"11","author":"L Morrison","year":"2024","unstructured":"Morrison, L., Saynor, Z. L., Kirk, A. & McCann, L. Revolutionizing care: unleashing the potential of digital health technology in physiotherapy management for people with cystic fibrosis. JMIR Rehabil. Assist Technol. 11, e55718 (2024).","journal-title":"JMIR Rehabil. Assist Technol."},{"key":"1137_CR38","unstructured":"Unlearn works with pharma sponsors, biotech companies, and academic institutions. https:\/\/www.businesswire.com\/news\/home\/20220419005354\/en (2022)."},{"key":"1137_CR39","unstructured":"Clinerion. https:\/\/www.clinerion.com\/index.html (2025)."},{"key":"1137_CR40","unstructured":"Deep 6 AI. https:\/\/deep6.ai\/ (2025)."},{"key":"1137_CR41","doi-asserted-by":"publisher","first-page":"191","DOI":"10.1038\/s43856-023-00425-3","volume":"3","author":"B Zhang","year":"2023","unstructured":"Zhang, B. et al. Harnessing artificial intelligence to improve clinical trial design. Commun. Med. 3, 191 (2023).","journal-title":"Commun. Med"},{"key":"1137_CR42","unstructured":"Rare Diseases Clinical Research Network. https:\/\/www.rarediseasesnetwork.org\/ (2025)."},{"key":"1137_CR43","doi-asserted-by":"publisher","first-page":"1127","DOI":"10.1016\/S0140-6736(19)32179-8","volume":"394","author":"S Zhang","year":"2019","unstructured":"Zhang, S., Chen, L., Zhang, Z. & Zhao, Y. Orphan drug development in China: progress and challenges.  Lancet 394, 1127\u20131128 (2019).","journal-title":"Lancet"},{"key":"1137_CR44","doi-asserted-by":"publisher","DOI":"10.1186\/s13023-023-02837-9","volume":"18","author":"S Witt","year":"2023","unstructured":"Witt, S., Schuett, K., Wiegand-Grefe, S., Boettcher, J. & Quitmann, J. Living with a rare disease - experiences and needs in pediatric patients and their parents. Orphanet J. Rare Dis. 18, 242 (2023).","journal-title":"Orphanet J. Rare Dis."},{"key":"1137_CR45","doi-asserted-by":"publisher","first-page":"54","DOI":"10.1186\/s44247-023-00051-y","volume":"1","author":"EV Nardo","year":"2023","unstructured":"Nardo, E. V. et al. The effect of an adapted digital mental health intervention for sickle cell disease on engagement: a pilot randomized controlled trial. BMC Digit Health 1, 54 (2023).","journal-title":"BMC Digit Health"},{"key":"1137_CR46","doi-asserted-by":"crossref","unstructured":"Moses, J. C., Adibi, S., Shariful Islam, S. M., Wickramasinghe, N. & Nguyen, L. Application of smartphone technologies in disease monitoring: a systematic review. Healthc. 9, 889 (2021).","DOI":"10.3390\/healthcare9070889"},{"key":"1137_CR47","unstructured":"The Medidata platform. https:\/\/www.medidata.com\/en\/clinical-trial-products\/unified-platform\/ (2025)."},{"key":"1137_CR48","unstructured":"Veeva Systems. https:\/\/www.veeva.com\/ (2025)."},{"key":"1137_CR49","unstructured":"Oracle Health Sciences. https:\/\/www.oracle.com\/health\/ (2025)."},{"key":"1137_CR50","doi-asserted-by":"publisher","first-page":"2","DOI":"10.1186\/s44247-022-00003-y","volume":"1","author":"Z Dai","year":"2023","unstructured":"Dai, Z. Telehealth in long-term care facilities during the Covid-19 pandemic \u2013 Lessons learned from patients, physicians, nurses and healthcare workers. BMC Digital Health 1, 2 (2023).","journal-title":"BMC Digital Health"},{"key":"1137_CR51","doi-asserted-by":"publisher","first-page":"e1587","DOI":"10.1016\/S2214-109X(24)00341-3","volume":"12","author":"AH Jonker","year":"2024","unstructured":"Jonker, A. H., Cavaller-Bellaubi, M., Nishimura, Y. & Pearce, D. A. Access in the rare diseases landscape.  Lancet Glob. Health 12, e1587 (2024).","journal-title":"Lancet Glob. Health"},{"key":"1137_CR52","doi-asserted-by":"publisher","first-page":"84","DOI":"10.1038\/s41746-024-01083-y","volume":"7","author":"N Mehandru","year":"2024","unstructured":"Mehandru, N. et al. Evaluating large language models as agents in the clinic. npj Digit. Med. 7, 84 (2024).","journal-title":"npj Digit. Med."},{"key":"1137_CR53","doi-asserted-by":"crossref","unstructured":"The increasing potential and challenges of digital twins. Nat. Comput. Sci. 4, 145\u2013146 (2024).","DOI":"10.1038\/s43588-024-00617-4"},{"key":"1137_CR54","doi-asserted-by":"publisher","first-page":"49","DOI":"10.1038\/s41591-022-02160-z","volume":"29","author":"V Subbiah","year":"2023","unstructured":"Subbiah, V. The next generation of evidence-based medicine. Nat. Med. 29, 49\u201358 (2023).","journal-title":"Nat. Med."},{"key":"1137_CR55","doi-asserted-by":"publisher","first-page":"184","DOI":"10.1038\/s43588-024-00607-6","volume":"4","author":"R Laubenbacher","year":"2024","unstructured":"Laubenbacher, R., Mehrad, B., Shmulevich, I. & Trayanova, N. Digital twins in medicine. Nat. Comput. Sci. 4, 184\u2013191 (2024).","journal-title":"Nat. Comput. Sci."},{"key":"1137_CR56","doi-asserted-by":"publisher","first-page":"5465","DOI":"10.1093\/bioinformatics\/btaa1026","volume":"36","author":"S Sinisi","year":"2021","unstructured":"Sinisi, S., Alimguzhin, V., Mancini, T., Tronci, E. & Leeners, B. Complete populations of virtual patients for in silico clinical trials. Bioinformatics 36, 5465\u20135472 (2021).","journal-title":"Bioinformatics"},{"key":"1137_CR57","doi-asserted-by":"publisher","first-page":"AIcs2400360","DOI":"10.1056\/AIcs2400360","volume":"2","author":"M Wornow","year":"2025","unstructured":"Wornow, M. et al. Zero-shot clinical trial patient matching with LLMs. NEJM AI 2, AIcs2400360 (2025).","journal-title":"NEJM AI"},{"key":"1137_CR58","doi-asserted-by":"publisher","first-page":"1953","DOI":"10.1093\/jamia\/ocae073","volume":"31","author":"M Nievas","year":"2024","unstructured":"Nievas, M., Basu, A., Wang, Y. & Singh, H. Distilling large language models for matching patients to clinical trials. J. Am. Med. Inform. Assoc. 31, 1953\u20131963 (2024).","journal-title":"J. Am. Med. Inform. Assoc."},{"key":"1137_CR59","doi-asserted-by":"publisher","unstructured":"Liu, N. et al. Large language models in randomized controlled trials design. https:\/\/doi.org\/10.21203\/rs.3.rs-4254962\/v1 (2024).","DOI":"10.21203\/rs.3.rs-4254962\/v1"},{"key":"1137_CR60","doi-asserted-by":"crossref","unstructured":"Reinisch, M., He, J., Liao, C., Siddiqui, S. & Xiao, B. CTP-LLM: Clinical trial phase transition prediction using large language models. In Proc. 2024 IEEE International Conference on Bioinformatics and Biomedicine (BIBM) 3667\u20133672 (IEEE, Lisbon, Portugal, 2024).","DOI":"10.1109\/BIBM62325.2024.10822746"},{"key":"1137_CR61","doi-asserted-by":"publisher","first-page":"e390","DOI":"10.1016\/S2589-7500(23)00052-3","volume":"5","author":"E Vayena","year":"2023","unstructured":"Vayena, E., Blasimme, A. & Sugarman, J. Decentralised clinical trials: ethical opportunities and challenges.  Lancet Digital Health 5, e390\u2013e394 (2023).","journal-title":"Lancet Digital Health"},{"key":"1137_CR62","doi-asserted-by":"publisher","first-page":"337","DOI":"10.1017\/S0963180116000931","volume":"26","author":"A Shenoy","year":"2017","unstructured":"Shenoy, A. & Appel, J. M. Safeguarding confidentiality in electronic health records. Camb. Q. Healthc. Ethics 26, 337\u2013341 (2017).","journal-title":"Camb. Q. Healthc. Ethics"},{"key":"1137_CR63","doi-asserted-by":"publisher","first-page":"e1091","DOI":"10.1016\/S2214-109X(24)00189-X","volume":"12","author":"A Gerk","year":"2024","unstructured":"Gerk, A., Kundu, S., Meara, J. G. & Stegmann, J. Digital solutions for rare diseases in global health.  Lancet Glob. Health 12, e1091 (2024).","journal-title":"Lancet Glob. Health"},{"key":"1137_CR64","doi-asserted-by":"publisher","first-page":"e1192","DOI":"10.1016\/S2214-109X(24)00134-7","volume":"12","author":"G Baynam","year":"2024","unstructured":"Baynam, G. et al. Global health for rare diseases through primary care.  Lancet Glob. Health 12, e1192\u2013e1199 (2024).","journal-title":"Lancet Glob. Health"}],"container-title":["Communications Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s43856-025-01137-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s43856-025-01137-6","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s43856-025-01137-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,31]],"date-time":"2025-10-31T18:03:01Z","timestamp":1761933781000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s43856-025-01137-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,10,31]]},"references-count":64,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["1137"],"URL":"https:\/\/doi.org\/10.1038\/s43856-025-01137-6","relation":{},"ISSN":["2730-664X"],"issn-type":[{"value":"2730-664X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,10,31]]},"assertion":[{"value":"11 April 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"26 August 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"31 October 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"T.W. is the deputy group chief executive officer (research and education) of Singapore Health Services, a consultant & advisory board for Allergan, Bayer, Boehringer-Ingelheim, Genentech, Merck, Novartis, Oxurion (formerly ThromboGenics), Roche, and co-founder of plano and EyRiS. The remaining authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"449"}}